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Background: We have previously identified the cancer-type organic anion transporting polypeptide 1B3 (Ct-OATP1B3)
mRNA in several human colon and lung cancer tissues. Ct-OATP1B3 is a variant of the liver-type OATP1B3 (Lt-OATP1B3)
mRNA, which is a hepatocyte plasma membrane transporter with broad substrate specificity. However, in cancer
tissues, both the detailed characteristics of Ct-OATP1B3 mRNA expression and its biological functions remain unclear.
With this point in mind, we sought to characterize Ct-OATP1B3 mRNA expression in colon and lung cancer tissues. In
addition, we attempted to obtain functional implication of Ct-OATP1B3 in cancer cells.
Methods: Matched pairs of cancer and normal tissues were collected from 39 colon cancer and 28 lung cancer
patients. The OATP1B3 mRNA expression levels in each of these tissues were separately determined by quantitative
real-time polymerase chain reaction. Mann–Whitney U test and Fisher’s exact test were used in statistical analysis. The
Ct-OATP1B3 functional expression in colon cancer cells was then examined by Western blotting and transport analyses.
Results: Ct-OATP1B3 mRNA, but not Lt-OATP1B3 mRNA, was abundantly expressed in colon cancer tissues at a
higher detection frequency (87.2%) than that of the adjacent normal tissues (2.6%). Furthermore, it was found that
Ct-OATP1B3 mRNA expression was often detected in early colon cancer stages (88.9%, n = 18), and that its expression
was associated with well-differentiated colon cancer statuses. On the other hand, Ct-OATP1B3 mRNA also showed a
predominant and cancer-associated expression profile in lung tissues, although at frequencies and expression levels
that were lower than those obtained from colon cancer. As for attempts to clarify the Ct-OATP1B3 functions, neither
protein expression nor transport activity could be observed in any of the cell lines examined.
Conclusions: Based on the unique characteristics of the Ct-OATP1B3 mRNA expression profile identified in this study,
Ct-OATP1B3 mRNA can be expected to become a biomarker candidate for use in colon (and lung) cancer diagnosis.
Simultaneously, our results advance the possibility that Ct-OATP1B3 might play yet unidentified roles, in addition to
transporter function, in cancer cell biology.
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It has been acknowledged that early detection and appro-
priate treatment are essential for overcoming the high
mortality and morbidity of cancer, and recent advances
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in any medium, provided the original work is pcancer therapy can contribute significantly to the develop-
ment of more sensitive and accurate detection methods,
as well as to the improvement of treatment outcomes in
various types of cancer. As part of these extensive ongoing
research efforts aimed at identifying molecules closely
associated with cancer, the specific aberrant mRNA
products found in cancer cells have attracted significant
levels of attention [1-3]. Recent findings have shown that
those aberrant gene products are among the hallmarks of
cancer, and that they often play a role in an oncogenicOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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epidermal growth factor receptor 2 splicing variant with
breast cancer cell invasion and trastuzumab resistance [4].
Thus, the characterizations of cancer-associated alterna-
tive mRNA products offer clear opportunities not only for
development of diagnostic, prognostic, and therapeutic
methods for cancer treatment, but also for gaining new
insights into cancer biology.
Recently, we have made our first report on the identifi-
cation of the cancer-type organic anion transporting
polypeptide 1B3 (Ct-OATP1B3, [GenBank: NM_019844
(for SLCO1B3, gene symbol) and GenBank: AB669023
(for the alternative region)] in human colon and lung
cancers [5], and other research groups have subsequently
confirmed its existence in colon and pancreas cancers
[6,7]. Ct-OATP1B3 is an mRNA variant of the liver-
specific OATP1B3 (which is hereafter referred to as the
liver-type OATP1B3, Lt-OATP1B3) that mediates cellular
uptake of a variety of endogenous compounds (e.g.,
cholecystokinin-octapeptide sulfated, CCK-8, or estradiol-
17β-D-glucuronide, E2G), as well as drugs (e.g., paclitaxel
or imatinib) at the basolateral membrane of hepatocytes
[8,9]. Previously, the detection of OATP1B3 (either or
both Ct- and Lt-OATP1B3) has been reported in various
cancer tissues, and it had been presumed that the mRNA
was identical to Lt-OATP1B3 [10-15]. However, in con-
trast with this presumption, our investigations, along with
others, have revealed that Ct-OATP1B3 mRNA expression
is strongly associated with cancerous colon and lung tis-
sues, but not with matched normal tissues or hepatocytes,
and that Ct-OATP1B3 mRNA is expressed predominantly
over Lt-OATP1B3 mRNA in these cancer tissues [5-7].
Therefore, those findings have shown that Ct-OATP1B3,
but not Lt-OATP1B3, is a primary mRNA isoform, at least
in these cancer tissues, which opens up the possibility of it
being an intriguing cancer-associated molecule that can
be used in the development of cancer biomarkers or
therapeutic targets. Nevertheless, our current understand-
ing of Ct-OATP1B3 mRNA expression profile in cancer
tissues remains premature due to a small number of
cancer tissues examined to date. Therefore, step-by-step
characterization of Ct-OATP1B3 mRNA expression using
a larger cohort will be required in order to validate and
increase the feasibility of its clinical application.
Another important issue that needs to be addressed is
clarification of the Ct-OATP1B3 function in cancer cells.
Because the Ct-OATP1B3 mRNA transcription start site
is located within the intron 2 of the SLCO1B3 gene [5],
Ct-OATP1B3 mRNA lacks the region that corresponds
to the Lt-OATP1B3 N-terminal coding region. There-
fore, the distinctive translation start codon usage is likely
to occur in Ct-OATP1B3 mRNA (Figure 1). Our original
research predicted a transporter-like translation product,
which we termed Ct-OATP1B3-C [5]. Although, basedon its deduced structure, Ct-OATP1B3-C is still expected
to have a transporter function like Lt-OATP1B3, its
functional expression remains to be demonstrated. Mean-
while, other studies have predicted the abilities of another
product, Ct-OATP1B3-v1. However, Thakkar et al. [6]
have reported that Ct-OATP1B3-v1 showed limited CCK-
8 transport activity owing to its predominant localiza-
tion in the cytoplasmic fraction, whereas Imai et al. [7]
reported the cell surface expression of Ct-OATP1B3-v1
with transporting activities against fluvastatin and rifam-
picin. Therefore, additional examinations are absolutely
essential to settling these controversies.
Based on all above-mentioned circumstances, this study
aimed at characterizing the Ct-OATP1B3 mRNA expres-
sion profile using a larger number of colon and lung
cancer tissue specimens, while simultaneously exploring its
application potential as a cancer biomarker. Furthermore,
we report on our attempt to identify a transporter-like
entity derived from Ct-OATP1B3 mRNA.
Methods
Human-derived materials
Thirty-nine matched-pairs of human colon cancer and
adjacent normal tissues were obtained from colon cancer
patients who had undergone surgery (from June 2011 to
June 2013) at the Chiba Cancer Center Research Institute
(Chiba, Japan). Twenty-eight matched-pairs of human
lung cancer and adjacent normal tissues were obtained
from lung cancer patients who had undergone surgery
(from January 2010 to February 2012) at the Chiba Uni-
versity Hospital (Chiba, Japan). The patient information is
shown in Tables 1 and 2. The source of human liver tissue
was described in our previous research [16]. Fifty donor-
pooled human hepatocytes (Hep50) were purchased from
Celsis IVT (Baltimore, MD). Use of human samples in this
study was approved by the Ethics Committees of Graduate
Schools of Pharmaceutical Sciences and Medicine, Chiba
University, and the Ethics Committee of the Chiba Cancer
Center Research Institute. Written informed consent was
obtained from each patient.
The tumor stages of the colon and lung cancer patients
were determined using the Union for International Cancer
Control (UICC) tumor-node-metastasis (TNM) classifi-
cation system. The differentiation status of colon cancer
tissues was determined by pathological examination.
Cells and cell culture
LS180 and HCT116 (colon cancer) cells were obtained
from DS Pharma Biomedical (Osaka, Japan) and Dr. B.
Vogelstein (Johns Hopkins University, Baltimore, MD),
respectively.
LS180 cells were cultured in Eagle's Minimum Essential
Medium (Wako, Osaka, Japan). HCT116 cells were main-
tained in Dulbecco's Modified Eagle's Medium (Wako).
BA
Figure 1 Schematic illustration of the Ct-OATP1B3 cDNA structure and its predicted translation products. (A) The cDNA structures of
Ct- and Lt-OATP1B3 along with their predicted translation products were shown. The sky-blue boxes indicate the Lt-OATP1B3-specific exons, while
the blue box indicates the Ct-OATP1B3-specific exon. The white boxes indicate the common exons. Each exon number is shown in the box. The
translation product of Lt-OATP1B3 or the predicted translation products of Ct-OATP1B3 (Ct-OATP1B3-C and Ct-OATP1B3-v1) are shown below the
cDNA structures. The red and black triangles indicate the translation start and stop codons, respectively. The open and closed arrows indicate an
isoform-specific primer set for Lt-OATP1B3 or Ct-OATP1B3 detection, respectively. (B) The 5’-end cDNA sequence of Ct-OATP1B3 (exon 1* to 3)
was shown. The bold blue letters indicate the predicted translation start codon (ATG) of Ct-OATP1B3-C or Ct-OATP1B3-v1. The underlines indicate
the key sequences supposedly determining translation efficiency, while the consensus Kozak sequence is 5’-A/GNNatgG-3’, where small “atg” is
the translation start codon.
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heat-inactivated fetal bovine serum and antibiotics. The
cells were grown at 37°C with 5% CO2.
Total RNA isolation and cDNA synthesis
Total RNA isolation from the human tissues and cells was
performed using an ISOGEN II (NipponGene, Tokyo,
Japan) according to the manufacturer’s protocol. cDNA
synthesis from extracted RNA (1 μg) was performed using
random hexamers as described previously [5].
Quantitative real-time polymerase chain reaction (qPCR)
qPCR was performed using the methods described in our
previous report [5]. Briefly, a SYBR green-based method
was used for Lt-OATP1B3 mRNA expression quantification
with the primer set (5’-AACAGCAGAGTCAGCATCTTCAG-3’ and 5’-AACATCTTGAATCCATTGCAGC-3’).
Ct-OATP1B3 mRNA expression level was determined
using a fluorescent probe-based method with the primer
set (5’-TTGGCTTGGGCTCAGAGA-3’ and 5’-TGCCAA
GAACATCTGCTAGTTT-3’), and universal probe #59
(Roche, Basel, Switzerland). The cDNA standard curve for
each OATP1B3 mRNA was synthesized from each
OATP1B3 mRNA at different copy numbers (from 103 to
108 copies for Ct-OATP1B3, and from 103 to 106 copies for
Lt-OATP1B3). Each OATP1B3 expression level (copies/ng
total RNA) in colon tissues, lung tissues, and cancer cell
lines was calculated using its corresponding standard curve
based on the condition that the mRNA expression level
below 103 copies/ng total RNA, which was regarded as the
level below the quantification limit (QL), the qPCR Ct-
value of which was over 35. The mRNA expression levels
Table 1 Demographic and clinical characteristics of colon
cancer patients
Variable N (total = 39)


















Unknown or unclassified 8
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patients), whereas those under the QL were regarded as
negative expression (or negative patients).
The total OATP1B3 mRNA (Ct- plus Lt-OATP1B3) and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH)Table 2 Demographic and clinical characteristics of lung
cancer patients
Variable N (total = 28)




Cancer type Adenocarcinoma 12
Squamous cell carcinoma 12
Adenosquamous carcinoma 1
Small cell carcinoma 1




Brinkman indexa <400 5
>400 23
aBrinkman index was calculated as the product of the number of cigarettes
smoked per day multiplied by the number of years of smoking.mRNA levels were respectively determined using universal
probe #59 with the primer set (5’-CGGCCTAACCTTG
ACCTATG-‘3 and 5’-TGAGTTGCAATAAGAAAGTGG
TACA-3’), and probe #60 with the primer set (5’-AGCCA
CATCGCTCAGACAC-‘3 and 5’-GCCCAATACGACCA
AATCC-3’). Data were calculated using the delta-delta-Ct
method, where the GAPDH mRNA levels were used as a
normalization control.
Western blot analysis
Whole cell lysates were prepared from each cancer cell
line using the lysis buffer or the Tris/Sucrose/EDTA
buffer. The soluble membrane fractions were prepared
from the whole cell lysates. Briefly, after centrifugation at
1,000 × g for 10 min, the supernatant was ultracentrifuged
at 100,000 × g for 45 min. Then, the soluble membrane
fractions were collected by dissolving the precipitates with
the Tris/Sucrose/EDTA buffer supplemented with 0.8%
(v/v) Nonidet P-40, 0.4% deoxycholic acid, and 0.08%
sodium dodecyl sulfate (SDS), followed by a second ultra-
centrifugation under the same conditions. Using the same
procedure, the soluble membrane fraction of human liver
tissue was prepared.
The proteins were separated by SDS-polyacrylamide gel
electrophoresis, and then transferred onto a polyvinylidene
difluoride membrane. The membrane was blocked with
5% skim milk for one hour at room temperature. Affinity
purified rabbit polyclonal anti-OATP1B3 antibodies, which
recognize the C-terminal region of Lt-OATP1B3, were used
as the primary antibodies (1,000-fold dilution, HPA004943,
Sigma, St. Louis, MO). Anti-Na+/K+ ATPase (1,000-fold
dilution, Sigma) and anti-β-actin (500-fold dilution, Sigma)
were also used. Immunocomplexes were detected with
ECL Western blotting detection reagents (GE Healthcare,
Giles, UK).
Transport assays
[3H]-CCK-8 and [3H]-E2G were obtained from PerkinElmer
(Boston, MA), while non-radiolabeled CCK-8 and E2G were
purchased from the Peptide Institute (Osaka, Japan) and
Sigma, respectively. The transport assay was performed
using LS180 and HCT116 cells based essentially on the
previously described method [17]. Final concentrations of
CCK-8 and E2G were 1 μM and 0.5 μM, respectively. The
transport activity for each substrate was determined within
a linear range (5 min). In the inhibition analysis, bromosul-
fophthalein (BSP, Sigma) (100 μM) was used.
Statistical analysis
Mann–Whitney U test was used to determine differences
of mRNA expression levels between two groups. Fisher’s
exact test was used to determine the univariate relation-
ship of the frequency of Ct-OATP1B3 or Lt-OATP1B3
mRNA expression between normal and cancer tissues. In
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expression data were used. All statistical analyses were
performed using the Statcel software (OMS Publishing
Inc., Tokyo, Japan).
Others
Detailed development methods for the Ct-OATP1B3-C
and Ct-OATP1B3-v1 expression plasmids, development
of human embryonic kidney (HEK) 293 cells transiently
or stably expressing each OATP1B3 isoform, as well as
anti-OATP1B3 rabbit serum preparation, are described
in Additional file 8 (supplemental materials and methods).
Experimental procedures for the Lt-OATP1B3 expression
plasmid and immunocytochemistry were described in the
previous report [18].
Results
Expression profile of each OATP1B3 mRNA isoform in
human colon cancer
Ct-OATP1B3 and Lt-OATP1B3 mRNA quantification
was performed using isoform-specific primer sets. The
results showed that Ct-OATP1B3 mRNA expression
frequencies in cancer and normal tissue specimens were
87.2% (34/39) and 2.6% (1/39), respectively (Fisher’s
exact test, P = 1.24 × 10−15) (Figure 2). In addition to this
high positive frequency, the mRNA levels in cancer tissues
were strikingly higher than those in normal tissues
(Figure 2). Accordingly, the apparent tumor/normal
expression ratio (the T/N ratio) of Ct-OATP1B3 mRNA
in each tissue pair was very high (Additional file 1: Figure































Figure 2 Expression profiles of Ct- and Lt-OATP1B3 mRNA in human
isoforms in each sample were separately determined by qPCR using the isofo
mRNA expression levels (copies/ng total RNA), which was obtained from thre
indicates the value of the quantification limit (QL). The total number of specim
each group is shown in parentheses. Horizontal solid lines denote the median
significance of median difference between two groups was examined using tcalculated due to the quantitatively undetectable Ct-
OATP1B3 mRNA levels in most normal tissues.
In contrast to the cancer-specific expression of Ct-
OTP1B3 mRNA, Lt-OATP1B3 mRNA expression fre-
quencies in cancer and normal tissue specimens were
53.8% (21/39) and 51.3% (20/39), respectively (Fisher’s
exact test, P = 0.5) (Figure 2). The median values of Lt-
OATP1B3 mRNA levels were similar between cancer
and normal tissues (Figure 2), and were strikingly lower
than those in human pooled hepatocytes (Table 3).
When the Ct- and Lt-OATP1B3 mRNA levels in cancer
tissues were compared, the median value of Ct-OATP1B3
mRNA levels in cancer tissues was 12.2-fold higher than
that of Lt-OATP1B3 mRNA levels (19.5 × 103 vs. 1.6 × 103
copies/ng total RNA, P = 2.9 × 10−6) (Figure 2). In addition,
Ct-OATP1B3 mRNA levels were also higher than Lt-
OATP1B3 mRNA levels in individual cancer specimens
(Additional file 2: Figure S2A).
It should be noted that the similar Ct- and Lt-OATP1B3
mRNA expression results were obtained using a ΔΔCt-
method with the GAPDH mRNA level used as a normal-
ization control (data not shown).
Taken together, our data showed that Ct-OATP1B3
mRNA was expressed in a cancer tissue-specific manner,
and that its mRNA expression was predominant over
Lt-OATP1B3 mRNA expression in colon cancer tissues.
Associations of Ct-OATP1B3 mRNA levels in colon cancer
tissues with clinico-pathological variables
Exploration of the clinico-pathological characteristics of
Ct-OATP1B3 mRNA expression profiles in colon cancerLt-OATP1B3
Normal Cancer
(20/39) (21/39)




colon cancer patients. The copy numbers of two OATP1B3 mRNA
rm-specific primers. Each dot represents the mean of Ct- or Lt-OATP1B3
e independent determinations, each performed in duplicate. The red line
ens, together with the number of positive expression specimens, in
value of positively detected mRNA levels in each group. The statistical
he Mann–Whitney U test.
Table 3 Ct-OATP1B3 and Lt-OATP1B3 mRNA levels in
colon tissues and pooled human hepatocytes
mRNA name Tissue (n)a Median value
(25-75th percentile)
(×103 copies/ng total RNA)
Ct-OATP1B3 Cancer (34) 19.5 (5.3-50.2)
Normal (1) N/Ab
Pooled hepatocytes N/Ac
Lt-OATP1B3 Cancer (21) 1.6 (1.2-2.4)
Normal (20) 1.4 (1.2-1.7)
Pooled hepatocytes 56.9 ± 2.5d
aThe number of Ct-OATP1B3 or Lt-OATP1B3 mRNA positive patients is shown
in parentheses.
bThe Ct-OATP1B3 mRNA copy number in the normal tissue is 4.3 × 103 copies/
ng total RNA.
cThe Ct-OATP1B3 mRNA expression level in pooled hepatocytes is under the
quantification limit.
dThe Lt-OATP1B3 mRNA expression level in pooled hepatocytes is expressed


































Figure 3 Comparison of the Ct-OATP1B3 mRNA expression levels
between well and moderately differentiated colon cancer tissues.
The colon cancer specimens with positive Ct-OATP1B3 mRNA expression
were classified into two groups by the degree of differentiation,
well-differentiated (n = 10), and moderately differentiated (n = 18).
Data are shown as the box-and-whisker plot. The statistical significance
of the median difference between two groups was determined using
the Mann–Whitney U test.
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OATP1B3 mRNA levels and expression frequencies with
cancer stages. As the results show, the Ct-OATP1B3
mRNA expression frequencies in early (0, I, and II) and
advanced (III and IV) cancer stages were 88.9% (16/18)
and 93.8% (15/16), respectively (Table 4). The median
Ct-OATP1B3 mRNA level tended to be higher in the
early stages than that in advanced stages (22.9 × 103 vs.
11.6 × 103 copies/ng total RNA, Table 4), although this
difference was not statistically significant (Mann–Whitney
U test, P = 0.3).
Next, to test the association of Ct-OATP1B3 mRNA
expression with the differentiation status of colon cancer,
the Ct-OATP1B3 mRNA levels between well-differentiated
and moderately differentiated cancer tissues were compared
(poorly differentiated and undifferentiated cancer tissues
could not be obtained for use in this study). The median
value of Ct-OATP1B3 mRNA levels in well-differentiated
cancer tissues was 5.2-fold higher than that in moder-
ately differentiated cancer tissues (58.1 × 103 vs. 11.2 × 103
copies/ng total RNA, Mann–Whitney U test, P = 0.004)
(Figure 3). It should be also noted that three out of
five cancer tissue specimens that did not express Ct-Table 4 Ct-OATP1B3 mRNA levels in early and advanced
stages of colon cancer tissues
Cancer stage Gene expression
frequency
Gene expression levelsa
% (n, positive/total) Median value
(25-75th percentile)
Early (0, I, and II) 88.9 (1/1, 2/2, and 13/15) 22.9 (11.1-62.2)
Advanced
(III and IV)
93.8 (12/12 and 3/4) 11.6 (4.8-32.7)
aThe value is expressed as × 103 copies/ng total RNA.OATP1B3 mRNA were moderately differentiated cancer
(the degree of differentiation in the rest two specimens
was unavailable) (data not shown).
Although the association of the Ct-OATP1B3 mRNA
levels with other factors (age, sex and tumor location)
was also examined, no statistically significant correlation
could be found (data not shown).Expression profile of each OATP1B3 mRNA isoform in
human lung cancer
Ct- and Lt-OATP1B3 mRNA in human lung cancer was
also separately quantified by qPCR. Compared with the
results obtained from colon cancer tissues, the Ct-
OATP1B3 mRNA expression frequency in lung cancer
was relatively low (28.6%, 8/28) (Figure 4). Nevertheless,
this frequency was statistically high compared with that
obtained from normal lung tissues (7.1%, 2/28) (Fisher’s
exact test, P = 0.039) (Figure 4), and the mRNA level in
each cancer tissue was higher than that in the matched
normal tissue (Additional file 1: Figure S1B).
Regarding Lt-OATP1B3 mRNA expression, its positive
frequencies in cancer and normal lung tissues were 7.1%
(2/28) and 3.6% (1/28) (Figure 4), and the Lt-OATP1B3
mRNA level was lower than the Ct-OATP1B3 mRNA
level in each matched pair (Additional file 2: Figure S2B).
Again, the similar Ct- and Lt-OATP1B3 mRNA expres-
sion results were obtained using a ΔΔCt-method with the






































Figure 4 Expression profiles of Ct- and Lt-OATP1B3 mRNA in human lung cancer patients. Using the same quantification and calculation
methods as described in the legend of Figure 2, the copy numbers of two OATP1B3 mRNA isoforms in each sample were separately determined.
Each dot represents the mean of Ct- or Lt-OATP1B3 mRNA expression levels (copies/ng total RNA), which was obtained from three independent
determinations, each performed in duplicate. The red line indicates the QL value. The total number of specimens, together with the number of
positive expression specimens, in each group is shown in parentheses.
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and lung cancer
When Ct-OATP1B3 mRNA levels between colon and
lung cancer tissues were compared, it was found that the
median value of Ct-OATP1B3 mRNA levels in colon
cancer tissues was 8.1-fold higher than that in lung
cancer tissues (19.5 × 103 vs. 2.4 × 103 copies/ng total
































Figure 5 Comparison of the Ct-OATP1B3 mRNA levels between
lung and colon cancer tissues. The Ct-OATP1B3 mRNA expression
levels in lung (n = 8) and colon (n = 34) cancer tissues are shown as
the box-and-whisker plot. Horizontal solid lines denote the median
mRNA levels in each group. The statistically significant difference of
the median Ct-OATP1B3 mRNA levels between two groups was
examined using the Mann–Whitney U test.Functional expression analysis of endogenous
Ct-OATP1B3 in colon cancer cell lines
The high Ct-OATP1B3 mRNA expression in cancer
tissues highlights the possibility that it plays certain
roles in cancer biology. Thus, the functional expression
analysis of Ct-OATP1B3 was performed using human
LS180 and HCT116 cells (colon cancer). The results
of mRNA quantification showed that, similar to those
observed in colon cancer tissues, Ct-OATP1B3 mRNA
was highly expressed in LS180 and HCT116 cells, and
that the mRNA level in LS180 cells was comparable
with that of Lt-OATP1B3 in pooled hepatocytes (Table 3,
Figure 6A).
Subsequently, endogenous Ct-OATP1B3 protein expres-
sion and functional analysis were performed by Western
blotting and transport assays. Despite high Ct-OATP1B3
mRNA expression levels in colon cancer cells, its protein
expression was not detected in the soluble membrane
fraction of such cells when using either anti-OATP1B3
antibodies (which was obtained from Sigma) or anti-
OATP1B3 rabbit serum (which was developed in this
study) (Figure 6 and Additional file 3: Figure S3). Na
+/K+ ATPase, which is a plasma membrane marker pro-
tein, was detected in all samples. Considering the possi-
bility that Ct-OATP1B3 could be localized somewhere
within intracellular fractions, the same analysis was also
performed using whole cell lysates. However, no Ct-
OATP1B3 protein expression was detected in any of
those cells (Additional file 4: Figure S4). Consistently,
CCK-8 transport activity was not detected in colon can-









































































Figure 6 Protein expression and functional analysis of Ct-OATP1B3 in colon cancer cell lines. (A) Quantification of Ct- and Lt-OATP1B3
mRNA expression levels in human pooled hepatocytes (Hep50) and colon cancer cells (LS180 and HCT116) was separately performed by qPCR.
The black and white bars indicate Ct- and Lt-OATP1B3 mRNA levels, respectively. The values are shown as means ± S.D. of three independent
experiments, each performed in duplicate. The dashed line indicates the QL value. (B) The membrane protein expression of Ct-OATP1B3 in colon
cancer cells was examined by Western blotting using rabbit anti-OATP1B3 antibodies that recognize the C-terminal peptide, which was supposed
to be the common region among both isoforms. The soluble membrane fraction of human liver tissue (HL) was used as a positive control. Na+/K+
ATPase was used for a plasma membrane marker. (C) The CCK-8 uptake was examined by transport analysis using LS180 and HCT116 cells. The CCK-8
uptake (1 μM) level was determined in the absence (black bar) or presence (gray bar) of BSP (100 μM). The CCK-8 uptake in cancer cells is expressed as
the relative ratio against the uptake of CCK-8 without BSP at 37°C. The white bar indicates transporter-independent CCK-8 accumulation level, which
was determined at 4°C. This experiment was performed three times in duplicate.
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were obtained from transport assay using E2G as a sub-
strate (data not shown).Ct-OATP1B3 functional expression analysis in cells
transfected with each Ct-OATP1B3 isoform expression
plasmid
We further examined the functional expression of Ct-
OATP1B3 using HCT116 cells transiently expressing
each OATP1B3 isoform. The immunocytochemistry and
transport assay results did not show any Ct-OATP1B3
protein expression or CCK-8 uptake activity in HCT116
cells transiently transfected with each Ct-OATP1B3
isoform (Additional file 5: Figure S5). However, Lt-
OATP1B3 protein expression, as well as its transportactivity, was clearly detected in the same experimental
condition.
Similar results were also obtained from HEK293 cells
stably expressing an OATP1B3 isoform (Additional file 6:
Figure S6). As expected, Lt-OATP1B3 expression and
function were clearly detected in HEK293 cells stably
expressing Lt-OATP1B3. However, despite comparable
mRNA levels among the cells, the results of Western
blotting and transport assays failed to show functional
Ct-OATP1B3 expression in any HEK293 cells expressing
either Ct-OATP1B3-C or CT-OATP1B3-v1.
Discussion
In agreement with our previous study, the results of the
present study have shown that, even when using a larger
number of the matched-pair tissue specimens, the Ct-
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tissue is always higher than the level in matched normal
tissues, and is always predominant over the Lt-OATP1B3
mRNA level in each cancer tissue. These findings can be
regarded as supporting evidence that Ct-OATP1B3 is the
bona fide OATP1B3 mRNA isoform expressed in human
colon and lung cancer. Thus, special attention should be
paid to Ct-OATP1B3 expression (rather than Lt-OATP1B3)
in future studies on cancer-associated OATP1B3. Further-
more, due to the high mRNA sequence similarities between
the two isoforms, an elaborative experimental design is
strongly recommended for such studies.
Cancer-specific RNA, DNA modification, or secreted
molecules have been used as cancer biomarkers, such as
carcinoembryonic antigen (CEA) and carbohydrate anti-
gen 19–9 (CA19-9) in colon cancer [19-21]. In addition,
numerous studies have been conducted to identify new
clinically useful cancer biomarkers, as exemplified by
Kallikrein-related peptidase 10 (KLK10) mRNA, which
shows a cancer-specific profile [22]. Accordingly, the high
positive rate (87.2%) of Ct-OATP1B3 mRNA expression
in colon cancer tissues, along with its high T/N ratio,
motivates us to evaluate it as a possible colon cancer
biomarker candidate. Cancer biomarkers should possess
sufficient and appropriate sensitivity and specificity that
allows them to fulfill their roles in a given cancer therapy
(cancer detection, metastasis or recurrence risk assessment,
or response prediction). Therefore, in order to evaluate
those properties, the area under the receiver operating
characteristic curve analysis has been widely used (higher
score is preferable with the maximum value = 1) [23].
A preliminary examination shows that the value of Ct-
OATP1B3 mRNA is 0.93 for colon cancer diagnosis
(Additional file 7: Figure S7). This value is comparable
to that of serum CEA (0.86) or KLK10 mRNA (0.89) and
higher than that of CA19-9 (0.58) [19,22], suggesting that
Ct-OATP1B3 mRNA may possess the clinically useful
level of diagnostic power necessary to discriminate
between cancer and normal colon tissues. In addition,
the newly-identified clinico-pathological Ct-OATP1B3
mRNA expression features, which are its high rate of
detection in early stages of colon cancer as well as its
association with the well-differentiated cancer status,
are considered noteworthy.
Based on the above considerations, it is reasonable to
expect that Ct-OATP1B3 mRNA may be a highly prom-
ising candidate of colon cancer biomarker. However, we
should reiterate the limitations of this study, which
underscore the necessity of further investigations using
an expanded cohort, various populations, and multicenter
analyses in order to produce a comprehensive evaluation of
its usefulness and restrictions. Elucidation of associations
between Ct-OATP1B3 mRNA expression and prognostic
values is another key issue that needs to be addressed(we were unable to pursue in this study due to use of
recently obtained tissue specimens). Furthermore, it will
be important to explore whether Ct-OATP1B3 mRNA can
be detected in blood, because it has become evident that
serum exosomes secreted from cancer cells contain cancer
cell–derived molecules [24], such as the tumor-specific
mRNA splicing variant detected in serum exosomes
obtained from several glioblastoma patients [25].
Taken together, although extensive research efforts will
be necessary before Ct-OATP1B3 mRNA can be estab-
lished as a colon cancer biomarker, it is considered likely
that such research will be worthwhile to promote in
view of the urgent need for diagnostic tools in colon
cancer, including the need for the development of a
more reliable and less-invasive detection marker for
patients in early stages of the disease. It has been acknowl-
edged that examination of serum CEA and CA19-9 does
not have sufficient capability for early identification of
colon cancer due to their low abnormality rates in stage
I (12-19% and 8%, respectively) and stage II patients
(47-49% and 17%, respectively) [20,21]. Therefore, once
established, it is speculated that Ct-OATP1B3 mRNA,
together with other markers and image diagnostic methods
such as colonoscopy, computerized tomography, and mag-
netic resonance imaging, may improve the accuracy
and sensitivity of current colon cancer screening, and may
provide other important clinico-pathological information
that ultimately contribute to reduction in the incidence of
morbidity and mortality of the disease.
In addition to colon cancer, Ct-OATP1B3 mRNAs were
also detected in about one third of lung cancer patients as
well. This finding suggests that Ct-OATP1B3 mRNA may
also be an indicator of lung cancer occurrence, although
to a lesser degree. In line with the observations that Ct-
OATP1B3 mRNA has been detected in other cancer types
[6,7], it will be necessary to clarify Ct-OATP1B3 mRNA
expression preference in various cancer types to expand
its clinical potential.
Functions of genes that are overexpressed in a cancer-
specific manner are often involved in oncogenic pro-
cesses [26-28]. Therefore, it is rational to assume that
association of Ct-OATP1B3 mRNA expression with well-
differentiation cancer status, as well as differential expres-
sion levels between lung and colon cancer, have some
links with certain cancer cell biological processes.
Based on the predicted transporter-like structure of Ct-
OATP1B3 translation products, which are Ct-OATP1B3-C
and Ct-OATP1B3-v1 (Figure 1), one of the plausible func-
tions of Ct-OATP1B3 is hormone uptake into cancer
cells, as has been reported with the OATP1A2 function
in prostate cancer [29]. The previous results provided by a
cell-based exogenous Ct-OATP1B3-v1 transient expression
system might also support this possibility [6,7]. However,
our results did not identify any functional expression of
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we able to identify exogenous Ct-OATP1B3 function in
HEK293 cells stably expressing Ct-OATP1B3-C or Ct-
OATP1B3-v1. Thus, these results show apparent inconsist-
encies regarding the functional expression of Ct-OATP1B3.
Because the experimental transport assay procedures
employed in those studies are quite similar, the reason
for the above-mentioned controversy is currently unclear.
Therefore, further research aimed at providing convincing
experimental evidence showing whether or not the Ct-
OATP1B3 protein exists will be necessary to solve the
above-mentioned arguments. However, in such future
studies, we suggest taking into consideration the possibil-
ity that the translation efficiency of Ct-OATP1B3-v1 or
Ct-OATP1B3-C might be very low. This is because the
genomic DNA sequence around the Ct-OATP1B3-v1 start
codon shows much less homology to the Kozak sequence
(Figure 1B) [30], and because Ct-OATP1B3-C has a long
5’-untranslated region.
Nevertheless, we believe it is important to publicize
our unexpected results pointing out that the transport
function may not be the major role of endogenous Ct-
OATP1B3 in cancer cells. This is because the results
provide, rather than exclude, additional possibilities
relating to how Ct-OATP1B3 plays a functional role in
cancer cell biology. Recently, it has been shown that
long non-coding RNA can directly interact with proteins
to promote cancer metastasis [31], while another report
has shown that a short cell-penetrating peptide derived
from the Wilm’s tumor protein 1 has inhibitory effects on
cancer proliferation and clonogenic activity [32]. In our
previous report, the existence of Ct-OATP1B3-derived
short peptides was suggested [5]. Therefore, while it is
already clear that Ct-OATP1B3 plays far-reaching roles
in cancer cells, numerous in vivo as well as in vitro
experiments still remain to be conducted. The results of
these experiments can be expected to provide important
clues that will help identifying the functions of Ct-
OATP1B3 protein, peptides, or the mRNA itself in cancer
cell biology.
Conclusion
Our results not only provide further evidence of the pri-
mary Ct-OATP1B3 mRNA expression profile in human
colon and lung cancer, but also identify new clinico-
pathological features of the Ct-OATP1B3 mRNA expres-
sion. Even though these results should be interpreted with
caution due to several study limitations, it can nevertheless
be said that Ct-OATP1B3 mRNA has the potential to
become a promising biomarker candidate for colon (and
lung) cancer diagnosis. On the other hand, our data
suggests that, although existence of a transporter-like
Ct-OATP1B3 protein cannot be fully excluded, it may
not functionally active at detectable levels. This highlightsthe need to give serious consideration to any molecules
potentially originating from the Ct-OATP1B3 gene in fur-
ther investigations aimed at obtaining a more precise un-
derstanding of the roles played by Ct-OATP1B3 in
cancer cells. We believe that such functional studies on
Ct-OATP1B3 will provide new insights into cancer
biology, while simultaneously enhancing translational
research into its role as a cancer biomarker candidate.Additional files
Additional file 1: Figure S1. The Ct-OATP1B3 mRNA expression T/N
ratio in each pair of the colon and lung tissues. The T/N ratio of Ct-OATP1B3
mRNA was calculated in individual colon cancer (A) and lung cancer (B)
patients who showed its positive expression, where the Ct-OATP1B3 mRNA
expression value of the normal tissue was set to the baseline. Ct-OATP1B3
mRNA levels in normal tissues were tentatively corrected as 103 copies/ng
total RNA (identical to the QL value) if the mRNA level was the QL. The
values obtained from each matched pair were connected by a line. Gray
lines indicate the T/N ratios that were calculated using the corrected values,
while the blue lines indicate the T/N ratios that were calculated using the
original values.
Additional file 2: Figure S2. Comparison between the Ct- and
Lt-OATP1B3 mRNA levels in each colon and lung cancer tissues. Fold
differences between Ct- and Lt-OATP1B3 mRNA levels were calculated
in individual colon cancer (A) and lung cancer (B) patients who showed
positive Ct-OATP1B3 mRNA expression in cancer tissue, where the
Lt-OATP1B3 mRNA level was set to the baseline. The Lt-OATP1B3 mRNA
levels in normal tissues were tentatively corrected as 103 copies/ng total
RNA (identical to the QL value) if the mRNA level was the QL. The values
obtained from an individual cancer tissue were connected by a line. The
gray lines indicate the fold differences that were calculated using the
corrected values, while the blue lines indicate the fold differences that
were calculated using the original values.
Additional file 3: Figure S3. Examination of Ct-OATP1B3 protein
expression in the soluble membrane fractions of colon cancer cells.
Western blotting was performed using the soluble membrane fraction
of LS180 or HCT116 cells with rabbit anti-OATP1B3 serum that was
developed by immunizing a rabbit with the synthesized epitope peptide
(LEFLNNGEHFVPSAGTD). A control rabbit serum was also used for
comparison. The soluble membrane fraction of human liver tissue (HL) was
used as a positive control. Na+/K+ ATPase was used as a membrane marker.
Additional file 4: Figure S4. Examination of Ct-OATP1B3 protein
expression in the whole cell lysates of colon cancer cells. Western blotting
was performed using the whole cell lysates of LS180 or HCT116 cells
with (A) rabbit polyclonal anti-OATP1B3 antibodies (Sigma) or (B) rabbit
anti-OATP1B3 serum (developed in this study). The soluble membrane
fraction of human liver tissue (HL) was used as a positive control. β-actin
was used as a loading control.
Additional file 5: Figure S5. Transient expression and functional analysis
of Ct-OATP1B3 in HCT116 cells. (A) Immunohistochemistry was performed
to examine the protein expression of each OATP1B3 isoform using HCT116
cells transiently transfected with the Lt1B3/p3.1 (Lt-1B3/HCT116), Ct1B3-C/
pBapo (Ct-1B3-C/HCT116), Ct1B3-v1/pBapo (Ct-1B3-v1/HCT116), or an empty
vector (mock/HCT116). The representative results that were obtained from
there independent experiments are shown. (B) The CCK-8 (1 μM) uptake by
Lt-1B3/HCT116, Ct-1B3-C/HCT116, Ct-1B3-v1/HCT116, or mock/HCT116 was
examined by transport analysis in the absence (black bar) or presence (white
bar) of BSP (100 μM). The uptake level of CCK-8 in Lt-1B3/HCT116, Ct-1B3-C/
HCT116 or Ct-1B3-v1/HCT116 cells was represented as the relative ratio to
that observed in mock/HCT116 cells. The experiment was performed three
times in duplicate.
Additional file 6: Figure S6. Stable expression and functional analysis
of Ct-OATP1B3 in HEK293 cells. (A) Either Ct-OATP1B3 or Lt-OATP1B3
mRNA expression level in human pooled hepatocytes (Hep50), Lt-1B3/
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http://www.clintransmed.com/content/3/1/37HEK, Ct-1B3-C/HEK, Ct-1B3-v1/HEK and mock/HEK, was determined by
qPCR using the primer set that could detect all mRNA isoforms, and the
results were normalized using those of GAPDH. Each mRNA expression
level is shown as mean ± S.D. of percentages relative to the level of pooled
human hepatocytes (100%). Experiments were performed three times in
duplicate. N.D. indicates that the value was too low to be calculated. (B) The
protein expression of either Ct-OATP1B3 or Lt-OATP1B3 in Ct-1B3-C/HEK,
Ct-1B3-v1/HEK, Lt-1B3/HEK, and mock/HEK, was examined by Western
blotting using the anti-OATP1B3 antibodies. The soluble membrane fraction
of human liver tissue (HL) was used as a positive control. Na+/K+ ATPase
was used for a plasma membrane marker. (C) The CCK-8 (1 μM, left) or E2G
(0.5 μM, right) uptake by Lt-1B3/HEK, Ct-1B3-C/HEK, Ct-1B3-v1/HEK and
mock/HEK was examined by transport analysis in the absence (black bar) or
presence (white bar) of BSP (100 μM). The uptake level of each substrate in
Lt-1B3/HEK, Ct-1B3-C/HEK or Ct-1B3-v1/HEK was represented as the relative
ratio to that observed in mock/HEK cells. The experiment was performed
three times in duplicate.
Additional file 7: Figure S7. Receiver operating characteristic (ROC)
analysis for Ct-OATP1B3 mRNA in colon cancer patients. To assess the
diagnostic potency of Ct-OATP1B3 mRNA in terms of its ability to
discriminate cancer tissues from normal tissues, the ROC curve was
generated on the basis of Ct-OATP1B3 mRNA levels in the matched-pairs
of colon cancer and normal tissues (n = 39). During this analysis, the
mRNA levels under the QL value were set to 103 copies/ng total RNA
(identical to the QL value) and used in the calculation. The area under
the ROC curve (AUC) along with its 95% confidence intervals (CI) was
analyzed using Prism 6 (GraphPad Software, La Jolla, CA). The AUC is
0.930 (95% CI = 0.865-0.994; P <0.0001).
Additional file 8: Supplemental materials and methods.
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